Glutamate (neurotransmitter)

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements

Retrieved on: 
Tuesday, January 16, 2024

Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.

Key Points: 
  • Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.
  • Led by SPRIM Global Investments Pte, Ltd, with key participation from core investors, this funding includes a $3.8 million credit facility.
  • Alongside these key developments, Stalicla will further strengthen the package supporting its second precision ASD asset, STP2.
  • Lynn Durham, CEO of Stalicla commented: “This financial backing underscores Stalicla's role as a trailblazer in the neuro precision space with first applications in precision psychiatry.

Addex to Present at Biotech Showcase™ 2024

Retrieved on: 
Friday, January 5, 2024

For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .

Key Points: 
  • For more information or to schedule a one-on-one meeting, please submit a request via the Biotech Showcase partnering platform or by sending an email to [email protected] .
  • Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders.
  • Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.

Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults

Retrieved on: 
Monday, October 30, 2023

This phase 1a open-label study evaluated the safety, tolerability, pharmacokinetics, and brain receptor occupancy of increasing doses of orally-administered ALX-001.

Key Points: 
  • This phase 1a open-label study evaluated the safety, tolerability, pharmacokinetics, and brain receptor occupancy of increasing doses of orally-administered ALX-001.
  • Single ascending doses were administered in 36 healthy adults between 50 and 80 years old with normal cognition.
  • The data were presented by principal investigator Adam Mecca, M.D., Ph.D. of the Yale School of Medicine Alzheimer’s Disease Research Unit.
  • Clinical research of ALX-001 in Alzheimer’s disease is advancing, with a Phase 1 multiple ascending dose study in healthy volunteers expected to finish in Q4 2023.

Allyx Therapeutics to Present Phase 1 Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer's Disease Meeting

Retrieved on: 
Thursday, October 19, 2023

NEW HAVEN, Conn., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage biotechnology company which is developing ALX-001, a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy for neurodegenerative diseases, today disclosed its plans to present the Phase 1 single ascending dose study results at the 16th Clinical Trials on Alzheimer's Disease (CTAD) meeting in Boston on October 27, 2023.

Key Points: 
  • ALX-001 continues to demonstrate promise in ongoing studies that build on twelve years of research.
  • The data will be presented by principal investigator Adam Mecca, M.D., Ph.D.
  • This study evaluated the safety, tolerability, pharmacokinetics, and brain receptor occupancy of increasing doses of orally-administered ALX-001.
  • “The potential for ALX-001 as a first-in-class oral therapy for neurodegenerative disease continues to be reinforced by a growing body of clinical evidence.”

Nobias Therapeutics Announces Acceptance of Late-Breaking Abstract and Presentation of Phase 2 Clinical Data for NB-001 at 52nd Child Neurology Society Annual Meeting

Retrieved on: 
Wednesday, September 20, 2023

MOUNTAIN VIEW, Calif. and PHILADELPHIA, Sept. 20, 2023 /PRNewswire-PRWeb/ -- Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover advanced therapeutics, today announced that new results from a Phase 2 clinical trial of NB-001 (fasoracetam) for the treatment of the neuropsychiatric symptoms associated with 22q11.2 deletion syndrome ("22q11DS") in children have been selected for a poster presentation at the 52nd Child Neurology Society (CNS) Annual Meeting, to be held October 4-7, 2023, in Vancouver, BC.

Key Points: 
  • Details on the presentation are as follows:
    "We are very pleased that this late-breaking abstract on NB-001 was accepted for presentation at the 52nd CNS Annual Meeting," said Neil Inala, President and CEO of Nobias Therapeutics.
  • 22q11DS, also known as DiGeorge syndrome, is a complex, phenotypically diverse genetic disease in which part of chromosome 22 is missing.
  • Each patient was randomly assigned to one of two treatment sequences: NB-001 followed by placebo or placebo followed by NB-001.
  • For more information about the CNS Annual Meeting, please visit https://www.childneurologysociety.org/ .

Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023

Retrieved on: 
Friday, August 4, 2023

Tokyo, Japan and Cambridge, UK, 4 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 4 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023.
  • Sosei Heptares will explore next steps with Pfizer for the future development of lotiglipron.
  • Revenue totalled JPY 2,146 million (US$15.9 million*), a decrease of JPY 311 million (US$4.1 million) vs. the prior corresponding period.
  • Core operating loss** totalled JPY 2,720 million (US$20.2 million) vs. a core operating loss of JPY 2,378 million (US$19.4 million) in the prior corresponding period.

Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023

Retrieved on: 
Friday, May 12, 2023

Tokyo, Japan and Cambridge, UK, 12 May 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 12 May 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “We are continuing to make good progress in building the foundation Sosei Heptares needs to become a leading international biopharmaceutical company headquartered in Japan by 2030.
  • This strategy is focused on (1) enhancing our platform; (2) progressing our partnerships; (3) transforming our R&D; and (4) commercializing products in Japan.
  • Revenue totalled JPY 943 million (US$7.1 million*), a decrease of JPY 176 million (US$2.5 million) vs. the prior corresponding period.

Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Capital

Retrieved on: 
Tuesday, March 7, 2023

The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital.

Key Points: 
  • The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital.
  • Following the close of the Series B financing, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the Board of Directors of Noema Pharma.
  • USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners.
  • Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.

Noema Pharma, Founded by Sofinnova Partners, Raises CHF 103 Million (USD 112 Million) in Series B Financing

Retrieved on: 
Tuesday, March 7, 2023

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx.

Key Points: 
  • Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx.
  • This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
    The Series B financing follows a CHF 54 million (approx.
  • USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners.
  • Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.